Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.95 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2,3-Dimercapto-1-Propanesulfonic Acid SCHEMBL25306432 | 1.00 | SLC22A6 (0.95) | SLC22A6NR1I2ALDH1A1LMNACYP1A2 | |
| 2,3-Dimercapto-1-Propanesulfonic Acid SCHEMBL1200084 | 0.97 | SLC22A6 (0.90) | SLC22A6NR1I2ALDH1A1LMNACYP1A2 | |
| 2,3-Dimercapto-1-Propanesulfonic Acid SCHEMBL135293 | 0.97 | — | — | |
| 2,3-Dimercapto-1-Propanesulfonic Acid SCHEMBL17744957 | 0.97 | — | — | |
| 2,3-Dimercapto-1-Propanesulfonic Acid SCHEMBL20483588 | 0.97 | — | — | |
| 2,3-Dimercapto-1-Propanesulfonic Acid SCHEMBL8086788 | 0.95 | SLC22A6 (0.95) | SLC22A6NR1I2ALDH1A1LMNACYP1A2 | |
| 2,3-Dimercapto-1-Propanesulfonic Acid SCHEMBL29364135 | 0.95 | SLC22A6 (0.95) | SLC22A6NR1I2ALDH1A1LMNACYP1A2 | |
| 2,3-Dimercapto-1-Propanesulfonic Acid SCHEMBL17749666 | 0.95 | SLC22A6 (0.95) | SLC22A6NR1I2ALDH1A1LMNACYP1A2 | |
| 2,3-Dimercapto-1-Propanesulfonic Acid SCHEMBL27877301 | 0.95 | SLC22A6 (0.95) | SLC22A6NR1I2ALDH1A1LMNACYP1A2 | |
| 2,3-Dimercapto-1-Propanesulfonic Acid SCHEMBL23787800 | 0.91 | SLC22A6 (0.78) | SLC22A6NR1I2ALDH1A1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 388 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240391942-A1 | HALOGENATED PHENYLARSINE OXIDE COMPOUND AND APPLICATION THEREOF | NUO-BETA PHARMACEUTICAL TECHNOLOGY (SHANGHAI) CO., LTD. (CN) | 2024-11-28 | — | — | US | claimed |
| CN-118103380-A | Halogenated benzene arsenic oxide compound and application thereof | 挪贝肽医药科技(上海)有限公司 | 2024-05-28 | — | — | CN | claimed |
| CN-114908386-B | Nanometer twin crystal copper foil with ultrathin multilayer structure, and preparation method and application thereof | 江西理工大学 | 2024-05-28 | — | — | CN | claimed |
| CN-117779125-A | Electroplating liquid medicine applied to large-aperture blind holes and process thereof | 永星化工(上海)有限公司 | 2024-03-29 | — | — | CN | claimed |
| CN-117603198-A | Method and device for rapidly detecting patulin in fruit and vegetable juice and beverage thereof | 深圳市易瑞生物技术股份有限公司 | 2024-02-27 | — | — | CN | claimed |
| WO-2023246889-A1 | ACID SULFATE ELECTROPLATING COPPER COMBINATION ADDITIVE FOR DENSE FILLING OF PCB THROUGH HOLE METAL | 厦门大学 | 2023-12-28 | — | — | WO | claimed |
| CN-116973200-A | Folic acid dissociating agent and application thereof | 中元汇吉生物技术股份有限公司 | 2023-10-31 | — | — | CN | claimed |
| CN-116926539-A | Nanocomposite film based on quantum dot layer-by-layer assembly and application thereof | 济南大学 | 2023-10-24 | — | — | CN | claimed |
| US-20230321599-A1 | METHOD OF AND DEVICE FOR REMOVING NITROGEN OXIDE IN GAS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-10-12 | — | — | US | claimed |
| CN-116655939-A | Keratin regenerated material with mercapto/disulfide bond dynamic covalent crosslinking system and preparation method thereof | 西安工程大学 | 2023-08-29 | — | — | CN | claimed |
| EP-1487431-A4 | PREVENTING AND/OR TREATING CARDIOVASCULAR DISEASE AND/OR ASSOCIATED HEART FAILURE | PROTEMIX CORP LTD (NZ) | 2006-10-25 | — | — | EP | claimed |
| US-20060148898-A1 | Curing and prophylactic agent applied during the use of alcohol and psychoactive substances | ZENOVICH SERGEI M | 2006-07-06 | — | — | US | claimed |
| WO-2005107723-A2 | TRANSDERMAL DELIVERY SYSTEMS AND TRANSDERMAL CHELATION PREPARATIONS | BUTTAR RASHID (US) | 2005-11-17 | — | — | WO | claimed |
| US-6951890-B2 | Preventing and/or treating cardiovascular disease and/or associated heart failure | PROTEMIX CORPORATION LIMITED (NZ) | 2005-10-04 | — | — | US | claimed |
| EP-1487431-A1 | PREVENTING AND/OR TREATING CARDIOVASCULAR DISEASE AND/OR ASSOCIATED HEART FAILURE | Protemix Corporation Limited (NZ) | 2004-12-22 | — | — | EP | claimed |
| WO-2004017957-A1 | PREVENTING AND/OR TREATING CARDIOVASCULAR DISEASE AND/OR ASSOCIATED HEART FAILURE | PROTEMIX CORPORATION LIMITED (NZ) | 2004-03-04 | — | — | WO | claimed |
| US-20030203973-A1 | Preventing and/or treating cardiovascular disease and/or associated heart failure | PHILERA NEW ZEALAND LIMITED (NZ) | 2003-10-30 | — | — | US | claimed |
| WO-2003077901-A1 | PREVENTING AND/OR TREATING CARDIOVASCULAR DISEASE AND/OR ASSOCIATED HEART FAILURE | PROTEMIX CORPORATION LIMITED (NZ) | 2003-09-25 | — | — | WO | claimed |
| WO-2003075910-A1 | PREVENTING AND/OR TREATING VASCULAR DISEASE, CARDIOMYOPATHY AND/OR ASSOCIATED HEART FAILURE | PROTEMIX CORPORATION LIMITED (NZ) | 2003-09-18 | — | — | WO | claimed |
| US-4382040-A | REACTING ALLYL HALIDE WITH A SULFITE, BROMINATION, REACTING WITH SODIUM HYDROGEN SULFIDE, FORMING A METAL COMPLEX AND REACTING WITH HYDROGEN SULFIDE | HEYL & CO. (DE) | 1983-05-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391942-A1 | HALOGENATED PHENYLARSINE OXIDE COMPOUND AND APPLICATION THEREOF | SLCO2B1, SLCO2A1, SLCO1B1 | SLC22A6 123/4885NR1I2 331/4885ALDH1A1 1702/4885 |
| US-20060148898-A1 | Curing and prophylactic agent applied during the use of alcohol and psychoactive substances | NEFM, CHRM2, PGM2 | SLC22A6 1066/4885NR1I2 3166/4885ALDH1A1 129/4885 |
| US-20030203973-A1 | Preventing and/or treating cardiovascular disease and/or associated heart failure | TNNI3, FABP3, TNNT2 | SLC22A6 913/4885NR1I2 910/4885ALDH1A1 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.